MariMed Reports Second Quarter 2025 Earnings
MRMDNORWOOD, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the second quarter ended June 30, 2025.
MariMed Q1 Adj. EPS $(0.01), Inline, Sales $37.95M Miss $38.45M Estimate
MRMDCannabis Co. MariMed Finalizes $11M Deal To Acquire First State Compassion
MRMDMariMed acquires First State Compassion, expanding its cannabis footprint in Delaware ahead of adult-use sales.
MariMed Q4 Adj EPS$(0.01), Inline, Sales $39.00M Miss $41.95M Estimate
MRMDMariMed Raises FY2024 Sales Guidance from $156.03M-159.00M to $157.51M-160.49M
MRMDExploring MariMed's Earnings Expectations
MRMDCannabis Company Launches Veterans Aid: $5K Grants For Housing Relief In Key Markets
MRMDEdibles Surge In The Heartland: MariMed's Play For Missouri And Illinois Cannabis Dominance
MRMDMariMed, a multi-state cannabis operator, is doubling down on its growth strategy by launching manufacturing operations in Missouri.
Cannabis Rescheduling Signals Strong Returns, Tax Breaks Could Increase This Stock's Market Cap By 170%
MRMDAccording to a recent report by Pablo Zuanic of Zuanic & Associates, MariMed (OTC: MRMD) a multi-state cannabis operator (MSO) is positioned for significant stock gains.
MariMed Completes Acquisition Of Kind Therapeutics USA, A Maryland Vertically Integrated Cannabis Business
MRMDMariMed Inc. (OTCQX: MRMD) completed the acquisition of Kind Therapeutics U.S.A., LLC.
